期刊
TRANSLATIONAL CANCER RESEARCH
卷 10, 期 5, 页码 2596-2608出版社
AME PUBLISHING COMPANY
DOI: 10.21037/tcr-20-2241
关键词
Immunotherapy; immune checkpoint inhibitors; radiation therapy; lung cancer; systemic therapy
类别
资金
- NIH/NCI Memorial Sloan Kettering Cancer Center Support Grant/Core Grant [P30-CA008748]
The combination of radiation therapy and immunotherapy has shown positive effects in the treatment of lung cancer, particularly in improving survival rates and reducing toxicity. Immune checkpoint inhibitors have shown new progress in the treatment of metastatic and locally advanced lung cancer.
Despite decreasing smoking rates, lung cancer remains the leading cause of death from cancer in the United States. Radiation therapy has been established as an effective locoregional therapy for both early stage and locally advanced disease and is known to stimulate local immune response. Past treatment paradigms have established the role of combining cytotoxic chemotherapy regimens and radiation therapy to help address the local and systemic nature of lung cancer. However, these regimens have limitations in their tolerability due to toxicity. Additionally, cytotoxic chemotherapy has limited efficacy in preventing systemic spread of lung cancer. Newer systemic agents such as immune checkpoint inhibitors have shown improved survival in metastatic and locally advanced lung cancer and have the advantage of more limited toxicity profiles compared to cytotoxic chemotherapy. Furthermore, improved overall response rates and systemic tumor responses have been observed with the combination of radiation therapy and immunotherapy, leading to numerous active clinical trials evaluating the combination of immune checkpoint inhibition with radiotherapy. This comprehensive review discusses the current clinical data and ongoing studies evaluating the combination of radiation therapy and immunotherapy in both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据